Small Molecule Protein Degrader for Rapid Target Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for manipulating protein expression post-translationally are limited, particularly in removing endogenous proteins, as they often require fusion proteins, gene knockout, or RNAi, which face challenges like slow protein depletion, off-target effects, and permeability issues, especially in mammals and clinical applications.
Innovation Solution
Development of compounds comprising a protein-binding moiety, a tag that promotes protein degradation, and a covalent linker to selectively enhance protein degradation, targeting specific proteins for therapeutic or research purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If gene knockout or RNAi methods are used to remove endogenous proteins, then protein levels can be reduced, but the process is slow (taking days) and may have off-target effects
Solution Approach 1:
The patent replaces the mechanical/biological systems of gene knockout and RNAi with a small molecule chemical system. The small molecule compound directly binds to the target protein and recruits the ubiquitin-proteasome system, achieving rapid protein degradation within hours rather than days, and avoiding off-target effects associated with genetic manipulation methods.
2Stability of the object's composition
If fusion proteins are used for post-translational modulation, then protein degradation can be induced, but the requirement for constant ligand presence is limiting and therapeutic use is nil
Solution Approach 1:
The patent extracts the degradation-inducing functionality from the constant ligand requirement. The small molecule compound is designed to bind the target protein directly and recruit degradation machinery, eliminating the need for constant ligand presence or fusion protein systems. The degradation is induced by the single administration of the small molecule, which then triggers the proteasomal degradation pathway.
3Measurement precision
If PROTACs are used to target protein degradation, then specific proteins can be degraded, but the use of peptide-based E3 ligase ligands limits therapeutic use and the ubiquitin pathways are too complicated
Solution Approach 1:
The patent replaces the complex peptide-based PROTAC system with a simplified small molecule approach. Instead of using peptide ligands that require complex ubiquitin pathway manipulation, the invention uses small molecule compounds that directly bind the target protein and recruit the proteasome, bypassing the need to navigate the complicated ubiquitin pathway and eliminating peptide stability issues.
4Quantity of substance
If RNAi is used for protein knockdown, then endogenous proteins can be reduced, but delivery and permeability hurdles must be surmounted for widespread use in mammals and clinic
Solution Approach 1:
The patent replaces the RNAi delivery system with a small molecule compound that can be administered systemically. Small molecules have inherent advantages in terms of cell permeability, metabolic stability, and ease of delivery compared to RNAi therapeutics. The compound can cross cell membranes and reach intracellular targets without requiring complex delivery vectors or transfection protocols.
Data Source
AI summary
Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein.